The management of chronic rhinosinusitis with nasal polyps (CRSwNP) is challenging due
to disease recurrence and adverse effects. Both surgical and medical treatment modalities
impact the quality of patients' lives. Monoclonal antibody treatment has recently been used
successfully in CRS with limited reported adverse events. We aimed to review the literature
to shed more light on the safety and adverse events associated with the biological therapy of
CRSwNP. A comprehensive systematic review was conducted on the safety of different …